A detailed history of American International Group, Inc. transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, American International Group, Inc. holds 30,877 shares of DAWN stock, worth $415,604. This represents 0.0% of its overall portfolio holdings.

Number of Shares
30,877
Previous 31,142 0.85%
Holding current value
$415,604
Previous $454,000 12.33%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

SELL
$13.56 - $17.46 $3,593 - $4,626
-265 Reduced 0.85%
30,877 $510,000
Q4 2023

Feb 13, 2024

SELL
$9.68 - $15.37 $1,219 - $1,936
-126 Reduced 0.4%
31,142 $454,000
Q3 2023

Nov 13, 2023

BUY
$11.22 - $14.86 $84,946 - $112,505
7,571 Added 31.95%
31,268 $383,000
Q2 2023

Aug 04, 2023

BUY
$11.74 - $14.47 $121,309 - $149,518
10,333 Added 77.32%
23,697 $282,000
Q1 2023

May 12, 2023

BUY
$12.75 - $23.41 $3,404 - $6,250
267 Added 2.04%
13,364 $178,000
Q4 2022

Feb 10, 2023

SELL
$18.77 - $22.0 $900 - $1,056
-48 Reduced 0.37%
13,097 $281,000
Q3 2022

Nov 14, 2022

BUY
$16.44 - $26.57 $36,431 - $58,879
2,216 Added 20.28%
13,145 $263,000
Q2 2022

Aug 12, 2022

SELL
$5.72 - $17.9 $2,087 - $6,533
-365 Reduced 3.23%
10,929 $196,000
Q1 2022

May 13, 2022

BUY
$9.12 - $17.47 $49,558 - $94,931
5,434 Added 92.73%
11,294 $112,000
Q4 2021

Feb 11, 2022

SELL
$15.65 - $26.33 $2,738 - $4,607
-175 Reduced 2.9%
5,860 $99,000
Q3 2021

Nov 12, 2021

BUY
$20.0 - $27.92 $120,700 - $168,497
6,035 New
6,035 $143,000

Others Institutions Holding DAWN

About Day One Biopharmaceuticals, Inc.


  • Ticker DAWN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 73,461,104
  • Market Cap $989M
  • Description
  • Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...
More about DAWN
Track This Portfolio

Track American International Group, Inc. Portfolio

Follow American International Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on American International Group, Inc. with notifications on news.